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Abstract
Introduction: The aim of the present study was to investigate the relationship between the blood IL-6 level, the
blood glucose level, and glucose control in septic patients.
Methods: This retrospective observational study in a general ICU of a university hospital included a total of 153
patients with sepsis, severe sepsis, or septic shock who were admitted to the ICU between 2005 and 2010, stayed
in the ICU for 7 days or longer, and did not receive steroid therapy prior to or after ICU admission. The severity of
stress hyperglycemia, status of glucose control, and correlation between those two factors in these patients were
investigated using the blood IL-6 level as an index of hypercytokinemia.
Results: A significant positive correlation between blood IL-6 level and blood glucose level on ICU admission was
observed in the overall study population (n = 153; r = 0.24, P = 0.01), and was stronger in the nondiabetic
subgroup (n = 112; r = 0.42, P < 0.01). The rate of successful glucose control (blood glucose level < 150 mg/dl
maintained for 6 days or longer) decreased with increase in blood IL-6 level on ICU admission (P < 0.01). The
blood IL-6 level after ICU admission remained significantly higher and the 60-day survival rate was significantly
lower in the failed glucose control group than in the successful glucose control group (P < 0.01 and P < 0.01,
respectively).
Conclusions: High blood IL-6 level was correlated with hyperglycemia and with difficulties in glucose control in
septic patients. These results suggest the possibility that hypercytokinemia might be involved in the development
of hyperglycemia in sepsis, and thereby might affect the success of glucose control.
Introduction
An elevated blood glucose level in critically ill patients is
termed stress hyperglycemia. Several studies have docu-
mented that stress hyperglycemia affects outcomes in
patients with various clinical conditions requiring inten-
sive care, such as myocardial infarction, cerebrovascular
disorders, or traumatic brain injury [1-3]. Hyperglycemia
has also been indicated to have deleterious effects on
patients with sepsis [4-6]. The Surviving Sepsis Cam-
paign guidelines have therefore consistently recom-
mended blood glucose control with a goal of < 150 mg/
dl, since the publication of the original version in 2004
[7-9].
In the pathophysiology of sepsis, proinflammatory
cytokines including TNFa, IL-1, and IL-6 are known to
play a pivotal role, and overproduced cytokines enter
into the bloodstream causing hypercytokinemia, which
leads to organ failure via humoral mediator network
activation and vascular endothelial damage [10,11].
We have routinely measured blood levels of IL-6 in all
patients with sepsis since 2000 to assess the severity of
hypercytokinemia, and we have reported the clinical
usefulness of the routine measurement of IL-6 levels in
septic patients [12,13]. Several other clinical studies have
also demonstrated that measurement of the blood IL-6
level is useful as a biomarker of hypercytokinemia
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[14-16]. We have also implemented blood glucose con-
trol in patients with sepsis according to the Surviving
Sepsis Campaign guidelines since 2004 [7]. Based on
our daily clinical experience in critical care of septic
patients, we hypothesize that a correlation exists
between the blood IL-6 level and hyperglycemia in
sepsis.
With this background, we retrospectively investigated
the correlation between blood IL-6 level and blood glu-
cose level in patients with sepsis. We also investigated
the relationship between the blood IL-6 level and glu-
cose control in the same patients.
Materials and methods
Patients
This retrospective observational study was conducted in
patients with sepsis who were admitted to the ICU of
Chiba University Hospital (an eight-bed general ICU
annually admitting approximately 800 to 1,000 medical/
surgical patients, both adult and pediatric) from 2005 to
2010. The inclusion criteria for this study were: age 18
years or older, and diagnosis with sepsis on ICU admis-
sion according to the definition of the American College
of Chest Physicians/Society of Critical Care Medicine
Consensus Conference [17]. The exclusion criteria were:
ICU stay shorter than 7 days (too short for sufficient
observation of changes in blood glucose level or appro-
priate determination of effects of glucose control), and
steroid therapy during the ICU stay (potentially influen-
cing blood glucose level and inflammatory reaction).
Prior to the initiation of critical care in the ICU, each
patient or his/her relative provided written informed
consent to possible research use of imaging and blood
testing data required for clinical practice as well as
information regarding the effectiveness of various treat-
ments, with confidentiality of personal information
secured. This retrospective study was approved by the
Chiba University Hospital Clinical Research Center
Ethics Committee before initiation of the research.
Patient management for glucose control
We have implemented blood glucose control in all sep-
tic patients, adopting the goal of < 150 mg/dl recom-
mended in the Surviving Sepsis Campaign guidelines
[7-9]. In addition to an upper-limit blood glucose goal
of < 150 mg/dl, a lower-limit blood glucose goal of >
100 mg/dl was adopted to minimize the risk of hypogly-
cemia. Arterial blood samples for blood glucose moni-
toring were collected via an intra-arterial pressure
monitoring line, and blood glucose was measured with a
glucose analyzer built in a blood gas analysis system
(Stat Profile pHOx Plus M; NOVA Biomedical Japan,
Tokyo, Japan).
Parenteral nutrition was initiated with glucose, amino
acids, and vitamins at 100 to 400 kcal/day. Early transi-
tion to enteral nutrition was attempted as soon as possi-
ble if the cardiopulmonary function of the patient was
stable, and unless there was bowel dysfunction in the
patient. In patients with septic shock, enteral nutrition
was initiated after recovery from shock. Total energy
intake was gradually increased by increasing doses of
enteral nutrition. Energy intake was also increased with
special care to avoid hyperglycemia. To reduce the
blood glucose level, regular insulin was continuously
administered intravenously using an infusion pump.
Measurement of the blood glucose level and adjustment
of the infusion rate of intravenous nutritional solution
and insulin were all implemented by intensivists only,
not by nurses and non-intensivist doctors. The intervals
of measurement of blood glucose level and adjustment
of infusion rate of intravenous nutrition solution and
insulin were basically 3 to 6 hours. However, intensivists
shortened measurement intervals, and changed glucose/
insulin doses more frequently, if they judged it
necessary.
According to the management protocol of the present
study, blood glucose control was performed in all
patients, aiming to achieve the blood glucose goals
within 24 hours after ICU admission. Successful blood
glucose control was defined as a blood glucose level of
< 150 mg/dl achieved within 24 hours after ICU admis-
sion and maintained thereafter within a range between
100 and 150 mg/dl for at least 6 days (that is, up to ICU
day 7).
Blood IL-6 measurement
The blood IL-6 level was determined by chemilumines-
cent enzyme immunoassay method. A rapid assay sys-
tem (Human IL-6 CLEIA; Fujirebio, Tokyo, Japan),
requiring an assay time of approximately 30 minutes,
was used for monitoring the blood IL-6 level with an
automated device (Lumipulse f®; Fujirebio) [12,13]. The
blood IL-6 level thus obtained was used as an index of
hypercytokinemia.
Comparative parameters and statistical analysis
All continuous variables are expressed as the mean ±
standard deviation. Normal distributions were confirmed
for all continuous variables other than the blood IL-6
level. The blood IL-6 level was used for statistical analy-
sis after logarithmic conversion, since a normal distribu-
tion was confirmed for logarithmically converted values
of this parameter.
Background parameters were compared between two
patient groups, those with successful glucose control
and those with failed glucose control, using the unpaired
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t test (continuous variables) and the chi-square test
(dichotomous variables). The correlation between blood
glucose level and blood IL-6 level on ICU admission
(that is, at baseline) was examined by calculating Pear-
son’s product-moment correlation coefficient. The cor-
relations between the blood glucose level and other
biomarkers (lactate, C-reactive protein, and so forth) or
severity scores, such as the Acute Physiology and
Chronic Health Evaluation (APACHE) II or the Sequen-
tial Organ Failure Assessment score on ICU admission
(that is, at baseline), were also examined by calculating
Pearson’s product-moment correlation coefficient.
The rate of successful blood glucose control was com-
pared among three patient groups stratified by blood IL-
6 level on ICU admission using the chi-square test.
Time-course changes in the blood glucose level, the
blood IL-6 level, energy intake, and insulin dose during
the ICU stay were compared between the successful and
failed blood control groups by repeated-measures analy-
sis of variance. For patients in the successful glucose
control group, the correlation between insulin dose on
ICU day 1 (required for achievement of blood glucose
goal < 150 mg/dl) and blood IL-6 level on ICU admis-
sion was further examined by calculating Pearson’s pro-
duct-moment correlation coefficient. The 28-day and
60-day survival rates were compared between the suc-
cessful and failed glucose control groups using the chi-
square test. Statistical package software (PASW Statistics
18 for Windows; SPSS Japan Inc., Tokyo, Japan) was




A total of 255 septic patients were admitted to our ICU
during the period from 2005 to 2010: 203 patients
stayed for 7 days or longer in the ICU, while 34 and 18
patients were discharged alive and dead, respectively,
from the ICU within 7 days and therefore were excluded
from this study. After further exclusion of 50 patients
having received steroids before or immediately after ICU
admission, 153 patients were finally included in this
study.
In the overall study population, subjects were aged
64.6 ± 14.2 years (mean ± standard deviation) and male
subjects comprised the majority (n = 109, 71.2%). The
APACHE II score of the total 153 patients was 23.5 ±
7.0 and the Sequential Organ Failure Assessment score
of the total 153 patients was 8.2 ± 3.5. Forty-one
patients (26.8%) had diabetes mellitus. The 153 patients
included 30 with sepsis (19.6%), 86 with severe sepsis
(56.2%), and 37 with septic shock (24.2%). Other back-
ground parameters are shown in Table 1. The back-
ground parameters were also compared between the
successful and failed glucose control groups. While the
percentage of male patients was significantly higher in
the successful glucose control group, no significant dif-
ference in age, medical/surgical ratio, or prevalence of
diabetes mellitus was observed between the two groups.
A significant difference in APACHE II score on ICU
admission was observed between the successful and
failed glucose control groups (P = 0.018). A significant
difference in the APACHE II score on ICU admission
was observed between the successful and failed glucose
control groups (P = 0.018). The lactate level and the IL-
6 level were also significantly different between the two
groups (P = 0.035 and P < 0.0001, respectively). The
percentage of patients with septic shock was signifi-
cantly higher in the failed glucose control group (P <
0.001).
Correlation between blood glucose level and various
parameters on ICU admission
Correlation coefficients (r) between the blood glucose
level and various parameters (age, APACHE II score,
Sequential Organ Failure Assessment score, lactate level,
white blood cells, C-reactive protein and IL-6 level)
were calculated and are shown in Table 2. In the analy-
sis of the study population, both the APACHE II score
and IL-6 level were weakly correlated with the blood
glucose level on ICU admission (APACHE II, r = 0.25, P
= 0.01; IL-6 level, r = 0.24, P = 0.01). When subgroup
analysis was performed on diabetic and nondiabetic
patients, a more significant positive correlation between
blood IL-6 level and blood glucose level on ICU admis-
sion was observed in the nondiabetic subgroup (r =
0.42, P < 0.01).
Rate of successful glucose control among three patient
groups stratified by blood IL-6 level on ICU admission
Figure 1 shows the rate of successful glucose control
calculated for three different patient groups stratified by
blood IL-6 level on ICU admission: < 1,000 pg/ml (low),
1,000 to 10,000 pg/ml (medium), and 10,000 pg/ml
(high). While the rate of successful glucose control on
the overall study population was 61.4% (55/75), the
values calculated for the low, medium, and high blood
IL-6 level groups were 73.3% (55/75), 64.4% (29/45), and
30.3% (10/38), respectively. A significant difference in
the rate of successful glucose control was demonstrated
among these three groups (P < 0.01, chi-square test).
Time-course changes in energy intake, insulin dose, blood
glucose level, and blood IL-6 level during an ICU stay
over 7 days between successful and failed glucose
control groups
Figure 2 shows a comparison of time-dependent changes
in energy intake, insulin dose, blood glucose level, and
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blood IL-6 level during the first 7 days of ICU stay
between the successful and failed glucose control
groups. Daily energy intake gradually increased during
the first 7 days of the ICU stay, with no significant dif-
ference between the two groups (P = 0.181; Figure 2a).
The daily insulin dose was significantly higher in the
failed glucose control group (P < 0.01; Figure 2b). The
daily insulin dose per 100 kcal energy intake was signifi-
cantly higher in the failed glucose control group than in
the successful glucose control group (P < 0.01; Figure
2c). The blood levels of glucose (P < 0.01; Figure 2d)
and IL-6 (P < 0.01; Figure 2e) were significantly higher
in the failed glucose control group both on ICU admis-
sion and thereafter. In the failed glucose control group
Table 1 Patients’ background factors





n 153 94 59
Age (years) 64.6 ± 14.2 65.4 ± 15.1 63.4 ± 12.6 0.394a
Gender (male) 109 (71.2%) 74 (78.7%) 35 (59.3%) < 0.01b
Medical/surgical, medical 57 (37.2%) 36 (38.3%) 21 (35.6%) 0.736b
Diabetes mellitus 41 (26.8%) 24 (25.5%) 17 (28.8%) 0.656b
On ICU admission
APACHE II score 23.5 ± 7.0 22.5 ± 7.1 25.2 ± 6.6 0.018a
SOFA score 8.2 ± 3.5 7.8 ± 3.7 8.7 ± 3.1 0.109a
White blood cells (/mm3) 14,300 ±
10,300
15,100 ± 10,800 13,000 ± 9,500 0.218a
C-reactive protein (mg/dl) 19.5 ± 10.0 18.6 ± 9.8 20.8 ± 10.3 0.203a
Lactate (mg/dl) 3.8 ± 2.8 3.4 ± 2.8 4.4 ± 2.8 0.035a
IL-6 (pg/ml) 13,800 ±
48,800
5,350 ± 13,800 27,200 ± 75,100 <
0.0001a
Type of sepsis < 0.001b
Sepsis 30 (19.6%) 27 (28.7%) 3 (5.1%)
Severe sepsis 86 (56.2%) 56 (59.6%) 30 (50.8%)
Septic shock 37 (24.2%) 11 (11.7%) 26 (44.1%)
Primary source of infection 0.276b
Central nervous system 5 (3.3%) 2 (2.1%) 3 (5.1%)
Neck/mediastinum 19 (12.4%) 11 (11.7%) 8 (13.6%)
Lung 45 (29.4%) 33 (35.1%) 12 (20.2%)
Abdomen 47 (30.7%) 25 (26.6%) 22 (37.3%)
Urinary tract 16 (10.5%) 8 (8.5%) 8 (13.6%)
Bones/joints/soft tissue 12 (7.8%) 7 (7.4%) 5 (8.5%)
Others 9 (5.9%) 8 (8.5%) 1 (1.7%)
Implementation of enteral nutrition within 7 days 89 (58.2%) 55 (58.5%) 34 (58.2%) 0.914b
Start of enteral nutrition after ICU admission
(days)
3.5 ± 2.1 3.7 ± 2.1 3.3 ± 2.1 0.446
Data presented as mean ± standard deviation or n (%). See ‘Patient management for glucose control’ in Materials and methods for definition of successful
glucose control. APACHE, Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment. aUnpaired t test. bChi-square test.
Table 2 Correlation between blood glucose level and various parameters on ICU admission
Glucose level (mg/dl) Overall (n = 153) Diabetes (n = 41) Nondiabetes (n = 112)
vs. age (years) 0.06 (0.47) 0.29 (0.06) 0.02 (0.81)
vs. APACHE II score 0.25 (0.01) 0.28 (0.07) 0.25 (0.01)
vs. SOFA score 0.09 (0.28) 0.09 (0.57) 0.06 (0.56)
vs. lactate (mg/dl) 0.03 (0.79) 0.02 (0.89) 0.08 (0.53)
vs. White blood cells (/mm3) 0.01 (0.92) 0.13 (0.40) 0.12 (0.23)
vs. C-reactive protein (mg/dl) 0.14 (0.09) 0.26 (0.10) 0.03 (0.79)
vs. IL-6 (pg/ml) 0.24 (0.01) 0.06 (0.62) 0.42 (< 0.01)
Data expressed as correlation coefficient (P value). Pearson’s product-moment correlation coefficients were calculated. APACHE, Acute Physiology and Chronic
Health Evaluation; SOFA: Sequential Organ Failure Assessment.
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compared with the successful glucose control group, the
blood glucose level remained higher in spite of a higher
dose of insulin, and the blood IL-6 level remained
higher.
Correlation between blood IL-6 level on ICU admission
and insulin dose on ICU day 1 in patients in the
successful glucose control group
Changes in the blood IL-6 level and daily insulin dose
were further investigated in the successful glucose con-
trol group (n = 94). Both the daily insulin dose and the
blood IL-6 level were the highest on ICU day 1 and
tended to gradually decrease over time thereafter (Figure
2c, e). A significant positive correlation was observed
between the values of these two parameters on ICU day
1 (r = 0.459, P < 0.01; Figure 3).
Outcomes
Hypoglycemia (glucose level < 60 mg/dl) occurred in
four of the 153 patients studied (2.6%), and one of the
four hypoglycemic patients died. The 28-day survival
rate was 89.5% in the overall study population: the sur-
vival rate in the successful glucose control group was
significantly higher than that in the failed glucose con-
trol group (94.6% vs. 81.4%, P < 0.01). The 60-day survi-
val rate in the overall study population was 80.4%, and
that in the successful glucose control group and the
failed glucose control group was 88.3%, and 67.8%,
respectively (P < 0.01; Table 3).
Discussion
In the present study we investigated the relationship
between the IL-6 level, the glucose level, and glucose
control in septic patients. The main findings of the pre-
sent study are as follows. First, a significant correlation
was observed between the blood IL-6 level and the
blood glucose level on ICU admission (Table 2). Second,
the rate of successful glucose control decreased with an
increase in the blood IL-6 level on ICU admission (Fig-
ure 1). Third, in the failed glucose control group the
insulin dose per 100 kcal energy intake was higher (Fig-
ure 2c) and glucose control was more difficult (Figure
2d), with the blood IL-6 level remaining higher (Figure
2e). Finally, a significant positive correlation was
observed between the blood IL-6 level and daily insulin
dose (required for achievement of the blood glucose
goal) on ICU day 1 in the successful glucose control
group (Figure 3). These results suggest that a high IL-6
level is associated with hyperglycemia and difficulties in
glucose control. Furthermore, in the comparison of each
parameter on ICU admission between the successful
and failed glucose control groups, the APACHE II score,
lactate level, and IL-6 level were significantly different. P
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Figure 1 Rate of successful glucose control among patients stratified by blood IL-6 level at ICU admission. Comparison of the rate of
successful glucose control among three patient groups stratified by blood IL-6 level at ICU admission. Examined by the chi-square test.
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highest when comparing all parameters (Table 1). In the
comparison of correlation coefficients between the
blood glucose level and various parameters, the correla-
tion coefficients between IL-6 and glucose levels in non-
diabetic patients were the highest of all of the
correlation coefficients, as shown in Table 2. From these
results, it is suggested that high IL-6 level is an indepen-
dent marker of severity of sepsis.
Proinflammatory cytokines play a pivotal role in the
pathophysiology of sepsis, and overproduced cytokines
enter the bloodstream causing hypercytokinemia, which
induces various pathophysiological changes and even-
tually results in organ failure [10,11]. We have measured
the blood level of IL-6 for real-time monitoring of the
severity of hypercytokinemia, and previously reported
the usefulness of blood IL-6 measurements in patients
with sepsis [12,13]. Although a limitation has existed in
single cytokine measurement, several other studies also
demonstrated that the blood level of IL-6 was useful as
a biomarker of hypercytokinemia [14-16].
While involvement of stress hormones (for example,
corticosteroids, glucagon, catecholamines) in the
mechanism of stress hyperglycemia has been repeatedly
described, proinflammatory cytokines can cause hyper-
glycemia by various mechanisms [4-6]. For example,
TNFa is known to induce insulin resistance by enhan-
cing secretion of stress hormones [18]. In a rat model of
zymosan-induced inflammatory response, Petit and col-
league reported that an increase in the blood TNFa
level induced a reduction in glucose uptake in skeletal
muscle [19]. IL-6 is known to inhibit tyrosine phosphor-
ylation of insulin receptor substrate-1 in isolated human
adipocytes, and thereby to suppress glycogen synthesis
[20]. In several clinical studies, the serum level of TNFa
or IL-6 was increased and glucose tolerance was
impaired in diabetics compared with nondiabetics
[21,22]. Combining these results of previous basic and
clinical research with our findings, these results suggest
that hypercytokinemia might be involved in the develop-
ment of hyperglycemia in sepsis and thereby might
affect the success of glucose control.
Although two large-scale clinical studies on glucose
control in septic patients previously failed to demon-
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Figure 2 Time-dependent changes in energy intake, insulin dose, blood glucose level, and blood IL-6 level. Comparison of time-course
changes between the successful and failed glucose control groups: (a) total energy intake, (b) insulin dose, (c) daily insulin dose per 100 kcal
energy intake, (d) blood glucose level, and (e) blood IL-6 level. Open symbols, successful glucose control group; shaded symbols, failed glucose
control group. Examined by repeated-measures analysis of variance.
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incidence of hypoglycemic events [23,24], recent review
articles suggest that stabilization of the blood glucose
level is important in the management of sepsis [4-6]. In
our present study, the patients with successful glucose
control showed better outcome than the patients with
failed glucose control (Table 3). These results from our
study also support the importance of glucose control in
septic patients.
































Dose of insulin administration on 1st  ICU day  
(IU/100kcal/day) 
Figure 3 Correlation between blood IL-6 level on ICU admission and insulin dose on ICU day 1. Correlation between the blood IL-6 level
on ICU admission and the insulin dose on ICU day 1 in patients in the successful glucose control group. Pearson’s product moment correlation
coefficient was calculated.
Table 3 Comparison of 28-day and 60-day survival rates between successful and failed glucose control groups
Overall Successful glucose control group Failed glucose control group P value
n 153 94 59
28-day survivors 137 (89.5) 89 (94.6) 48 (81.4) < 0.01a
60-day survivors 123 (80.4) 83 (88.3) 40 (67.8) < 0.01a
Data presented as n (%). See ‘Patient management for glucose control’ in Materials and methods for definition of successful glucose control. aChi-square test.
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While the clinical efficacy of glucose control in sepsis
has been demonstrated, our clinical experience suggests
that achievement of glucose control may remain diffi-
cult. Recently, three strategies of successful glucose con-
trol have been reported [25,26]. One strategy is
statistical process control using a newly developed glu-
cose control protocol on the basis of statistical analysis
of previous blood glucose level data [25]. Another is a
computer-generated alert system that involves an elec-
tronic blood glucose alert in the bedside computer [26].
The third strategy involves the application of an artificial
endocrine pancreas, a mechanical glucose control sys-
tem that is capable of automatic blood sampling at
short intervals, measurement of blood glucose levels,
and automatic adjustment of insulin and glucose dose
[27].
Considering that a high IL-6 level correlated with glu-
cose control in the present study, there is a possibility
that improving hypercytokinemia is a new strategy for
successful glucose control in addition to above three
strategies. Blood purification such as continuous hemo-
diafiltration is one of the most promising treatments
available for the treatment of hypercytokinemia [28,29].
We have reported that continuous hemodiafiltration
using a polymethylmethacrylate membrane hemofilter
with cytokine-adsorbing capacity successfully improved
hypercytokinemia [29]. Although there is little evidence,
these blood purifications might be expected to control
hypercytokinemia and thus to facilitate glucose control.
The present study has several limitations. First,
although we found correlation between a high IL-6 level
and hyperglycemia in the present study, it is difficult to
elucidate the interaction between high IL-6 level and
hyperglycemia. Previous studies suggest that high proin-
flammatory response might be one of the causes of
hyperglycemia. However, additional study is needed to
prove these mechanisms. Second, because there was a
weak correlation between the APACHE II score and
glucose level on ICU admission, we could not comple-
tely deny that IL-6-related hyperglycemia might be an
epiphenomenon of severe illness. Furthermore, the
observed difference in survival rate between the success-
ful and failed glucose control groups does not necessa-
rily demonstrate effectiveness of blood control in sepsis,
since there was a substantial difference in severity scores
between these two groups. Future studies employing
prospective designs may be needed to further elucidate
the relationship between hypercytokinemia and stress
hyperglycemia and the relationship between hypercyto-
kinemia and glucose control.
Conclusion
Our retrospective study including 153 patients with sep-
sis indicated that a high IL-6 level was correlated with
hyperglycemia and difficulties in glucose control. These
results suggest there is a possibility that hypercytokine-
mia might be involved in the development of hypergly-
cemia in sepsis, and that it might thereby affect the
success of glucose control.
Key messages
• In septic patients, a high IL-6 level, which is an
index of hypercytokinemia, correlated with hypergly-
cemia and difficulties in glucose control.
• Hypercytokinemia might therefore be involved in
the development of hyperglycemia in septic patients,
and might thereby affect the success of glucose
control.
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